The CAG repeat within exon 1 of the androgen receptor (AR) has been associated with the development of prostate cancer. The shorter number of glutamine residues in the protein has been associated with a higher transcriptional activity of the AR and increased relative risk for prostate cancer. In an attempt to identify differentially expressed genes in prostate cancer in relation to AR CAG repeat length variation, in this study we used total mRNA from normal and tumor tissues from 2 prostate cancer patients with AR alleles containing 19 and 26 CAG repeats to perform differential-display RT-PCR analysis. We were able to identify 48 different transcripts that showed homology to several known genes associated with different biological pathways. Among the differentially expressed genes, ATRX and SFRP1 were further validated by quantitative RT-PCR. The transcripts of both ATRX and SFRP1 genes proved to be down-regulated in most of the prostate tumors analyzed by quantitative RT-PCR. Hypermethylation of the promoter region of the SFRP1 gene was found in 17.5% (7/40) of the cases analyzed and was associated with the loss of SFRP1 expression (p=0.014). The differentially expressed genes identified in this study are implicated in several cellular pathways that, when up- or down-regulated, might play a role in the tumorigenic process of the prostate.
JemalA., TiwariR.C., MurrayT.Cancer statistics, 2004.CA Cancer J Clin2004; 54: 8–29.
2.
INCA (Instituto Nacional do Câncer) – Ministério da Saúde.www.inca.gov.br. Estimativa 2006: Incidência de Câncer no Brasil. Rio de Janeiro: INCA 2005.
3.
JensterG.The role of the androgen receptor in the development and progression of prostate cancer.Sem Oncol1999; 26: 407–21.
4.
IrvineR.A., YuM.C., RossR.K., CoetzeeG.A.The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer.Cancer Res1995; 55: 1937–40.
5.
GiovannucciE., StampferM.J., KrithivasK.The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.Proc Natl Acad Sci U S A1997; 94: 3320–3.
6.
GiovannucciE., PlatzE.A., StampferM.J.The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia.Urology1999; 53: 121–5.
7.
dos SantosM.L., SarkisA.S., NishimotoI.N., NagaiM.A.Androgen receptor CAG repeat polymorphism in prostate cancer from a Brazilian population.Cancer Detect Prev2003; 27: 321–6.
8.
PlatzE.A., GiovannucciE.The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer.J Steroid Biochem Mol Biol2004; 92: 237–53.
HakimiJ.M., SchoenbergM.P., RondinelliR.H., PiantadosiS., BarrackE.R.Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer.Clin Cancer Res1997; 3: 1599–608.
11.
HardyD.O., ScherH.I., BogenreiderT.Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset.J Clin Endocrinol Metab1996; 81: 4400–4.
12.
BeilinJ., HarewoodL., FrydenbergM.A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects.Cancer2001; 92: 941–9.
13.
ChamberlainN.L., DriverE.D., MesfeldR.L.The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function.Nucleic Acids Res1994; 22: 3181–6.
14.
BeilinJ., BallE.M., FavaloroJ.M., ZajacJ.D.Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines.J Mol Endocrinol2000; 25: 85–96.
15.
BuchananG., YangM., CheongA.Structural and functional consequences of glutamine tract variation in the androgen receptor.Hum Mol Genet2004; 13: 1677–92.
16.
ChoongC.S., KemppainenJ.A., ZhouZ.X., WilsonE.M.Reduced androgen receptor gene expression with first exon CAG repeat expansion.Mol Endocrinol1996; 10: 1527–35.
17.
IrvineR.A., MaH., YuM.C., RossR.K., StallcupM.R., CoetzeeG.A.Inhibition of p160-mediated coactivation with increased androgen receptor polyglutamine length.Hum Mol Genet2000; 9: 267–74.
18.
ChomczynskiP., SacchiN.Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.Anal Biochem1987; 162: 156–9.
19.
HernandezJ., ThompsonI.M.Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.Cancer2004; 101: 894–904.
20.
WissmannC., WildP.J., KaiserS.WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer.J Pathol2003; 201: 204–12.
21.
Lopez-FernandezL.A., del MazoJ.The cytosolic aldehyde dehydrogenase gene (Aldh1) is developmentally expressed in Leydig cells.FEBS Lett1997; 407: 225–9.
22.
McCammonD.K., ZhouP., TurneyM.K., McPhaulM.J., KovacsW.J.An androgenic affinity ligand covalently binds to cytosolic aldehyde dehydrogenase from human genital skin fibroblasts.Mol Cell Endocrinol1993; 91: 177–83.
23.
YanagawaY., ChenJ.C., HsuL.C., YoshidaA.The transcriptional regulation of human aldehyde dehydrogenase I gene. The structural and functional analysis of the promoter.J Biol Chem1995; 270: 17521–7.
24.
XuL.L., ShanmuganN., SegawaT.A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate.Genomics2000; 66: 257–63.
25.
XuL.L., SuY.P., LabicheR.Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes.Int J Cancer2001; 92: 322–8.
26.
De PrimoS.E., DiehnM., NelsonJ.B.Transcriptional programs activated by exposure of human prostate cancer cells to androgen.Genome Biol2002; 3: 1–12.
27.
XuL.L., ShiY., PetrovicsG.PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression.Cancer Res2003; 63: 4299–304.
28.
RattnerA., HsiehJ.C., SmallwoodP.M.A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors.Proc Natl Acad Sci U S A1997; 94: 2859–63.
29.
PolakisP.Wnt signaling and cancer.Genes Dev2000; 14: 1837–51.
30.
WangS., KrinksM., MoosM.Jr.. Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts – 3A, -5A or –11.Biochem Biophys Res Commun1997; 236: 502–4.
31.
KawanoY., KyptaR.Secreted antagonists of the Wnt signalling pathway.J Cell Sci2003; 116: 2627–34.
32.
UgoliniF., Charafe-JauffretE., BardouV.J.WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type.Oncogene2001; 20: 5810–7.
ToK.F., ChanM.W., LeungW.K.Alterations of frizzled (FzE3) and secreted frizzled related protein (hsFRP) expression in gastric cancer.Life Sci2001; 70: 483–9.
35.
StoehrR., WissmannC., SuzukiH.Deletions of chromosome 8p and loss of SFRP1 expression are progression markers of papillary bladder cancer.Lab Invest2004; 84: 465–78.
36.
VeeckJ., NiederacherD., AnH.Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis.Oncogene2006; Jan 30 [Epub ahead of print].
37.
SuzukiH., GabrielsonE., ChenW.A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.Nat Genet2002; 31: 141–9.
38.
TakadaT., YagiY., MaekitaT.Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.Cancer Sci2004; 95: 741–4.
39.
FlorlA.R., SteinhoffC., MüllerM.Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation.Br J Cancer2004; 91: 985–94.
JoestingM.S., PerrinS., ElenbaasB.Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer.Cancer Res2005; 65: 10423–30.
PickettsD.J., HiggsD.R., BachooS., BlakeD.J., QuarrellO.W.J., GibbonsR.J.ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndrome.Hum Molec Genet1996; 5: 1899–907.
44.
GibbonsR.J., BachooS., PickettsD.J.Mutations in transcriptional regulator ATRX establish the functional significance of a PHD-like domain.Nature Genet1997; 17: 146–8.
45.
CardosoC., LutzY., MignonC.ATR-X mutations cause impaired nuclear location and altered DNA binding properties of the XNP/ATR-X protein.J Med Genet2000; 37: 746–51.
46.
RastelliL., ChanC.S., PirrottaV.Related chromosome binding sites for zeste, suppressors of zeste and Polycomb group proteins in Drosophila and their dependence on Enhancer of zeste function.EMBO J1993; 12: 1513–22.
47.
CardosoC., TimsitS., VillardL., KhrestchatiskyM., FontesM., ColleauxL.Specific interaction between the XNP/ATR-X gene product and the SET domain of the human EZH2 protein.Hum Mol Genet1998; 7: 679–84.
48.
MahmoudiT., VerrijzerC.P.Chromatin silencing and activation by Polycomb and trithorax group proteins.Oncogene2001; 20: 3055–66.
49.
CarlsonM., LaurentB.C.The SNF/SWI family of global transcriptional activators.Curr Opin Cell Biol1994; 6: 396–402.
50.
GibbonsR.J., HiggsD.R.Molecular-clinical spectrum of the ATR-X syndrome.Am J Med Genet2000; 97: 204–12.
51.
BerubeN.G., JaglaM., SmeenkC., De RepentignyY., KotharyR., PickettsD.J.Neurodevelopmental defects resulting from ATRX over-expression in transgenic mice.Hum Mol Genet.2002; 11: 253–61.
52.
TangP., ParkD.J., Marshall GravesJ.A., HarleyV.R.ATRX and sex differentiation.Trends Endocrinol Metab2004; 15: 339–44.
53.
BoH., GhazizadehM., ShimizuH.Effect of ionizing irradiation on human esophageal cancer cell lines by cDNA microarray gene expression analysis.J Nippon Med Sch2004; 71: 172–80.
54.
LacayoN.J., MeshinchiS., KinnunenP.Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes.Blood2004; 104: 2646–54.
